Global Circular RNA Generation Technology Market Strategic Research Report

Scope of the Report

The global Circular RNA Generation Technology market size is predicted to grow from US$ 93.91 million in 2025 to US$ 559 million in 2032; it is expected to grow at a CAGR of 28.8% from 2026 to 2032.

Circular RNA generation technology comprises the methods and process systems used to produce covalently closed circular RNA through sequence design, DNA template construction, in vitro transcription, ribozyme-mediated self-splicing, enzymatic ligation, intracellular splicing, or vector-mediated expression. A complete manufacturing workflow generally includes precursor RNA design, transcription, circularization, removal of residual linear RNA and double-stranded RNA impurities, chromatographic purification, concentration and buffer exchange, structural confirmation, purity testing, expression activity evaluation, and delivery formulation development. Upstream inputs mainly include nucleotide triphosphates, modified nucleosides, DNA and plasmid templates, RNA polymerases, T4 RNA ligases, ribozyme elements, nucleases, buffers, chromatography media, ultrafiltration consumables, single-use bioprocessing materials, analytical reagents, and lipid nanoparticle materials. Downstream customers include RNA drug developers, vaccine companies, gene and cell therapy companies, pharmaceutical companies, CRO/CDMO providers, research institutes, and hospital research centers. The industry's gross margin in 2025 is estimated at approximately 45%–65%.

The circular RNA generation technology market is currently transitioning from a research-tool market into an enabling infrastructure market for RNA drug development. Research-grade custom synthesis, vector construction, and circularization kits continue to represent the basic demand base, while faster growth is occurring in process development, impurity control, analytical method establishment, and GMP manufacturing. Suppliers can generally be divided into three groups: therapeutic developers with proprietary circularization platforms, life-science companies providing research-grade synthesis and kits, and RNA CRO/CDMO companies capable of producing clinical-grade drug substance and formulated products. The United States and China are currently the most active supply regions. Chinese companies have established a relatively broad presence in custom synthesis, process services, and integrated manufacturing, while U.S. companies are more active in proprietary platforms, technology licensing, and therapeutic translation.

Future technology development will shift from maximizing circularization yield alone toward the combined optimization of product integrity, scarless ligation, sequence flexibility, long-transcript compatibility, and manufacturing reproducibility. Conventional PIE approaches have a relatively mature research foundation, but may introduce residual foreign sequences and constrain some sequence designs. Enzymatic ligation approaches can provide more flexible or scarless products, but impose greater requirements on terminal structure, splint design, and enzyme cost. New intact-intron self-splicing, nickless circularization, and integrated circularization-purification technologies are emerging and may reduce impurity burdens and downstream purification complexity. In vitro and intracellular generation routes are expected to coexist, with the former offering better manufacturing control and the latter supporting sustained expression in gene therapy and in vivo cell-reprogramming applications.

Market growth is being driven by the development of next-generation RNA drugs, therapeutic vaccines, in vivo cell therapies, protein-replacement therapies, and genetic medicines. Once circular RNA programs advance into clinical development, demand expands beyond basic RNA synthesis to include high-purity drug substance, residual linear RNA and double-stranded RNA testing, structural characterization, translation-efficiency testing, aseptic production, and regulatory documentation. This substantially increases the value of each project. Downstream developers are also increasingly outsourcing sequence design, template preparation, circularization, purification, analytics, and LNP formulation to integrated suppliers in order to reduce technology-transfer risks and accelerate regulatory submissions. Entry by large pharmaceutical companies and expansion by specialist CDMOs are expected to support more standardized technical and supply-chain practices.

The main barriers are the lack of harmonized evaluation standards across circularization methods and the fact that a high circularization rate does not necessarily result in high purity, strong expression, or low immunogenicity. Uncircularized precursors, mis-ligated products, residual linear RNA, double-stranded RNA, truncated transcripts, and residual DNA can all affect safety and biological activity, placing substantial demands on purification and analytical methods. Long-sequence circularization, batch reproducibility, manufacturing scale-up, enzyme costs, and limited regulatory standards remain major industrialization challenges. The patent landscape is also complex, with overlapping claims covering PIE systems, ligase methods, translation elements, purification processes, and delivery technologies, creating uncertainty around freedom to operate and commercial licensing.

This report presents a comprehensive overview of the global Circular RNA Generation Technology market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• In Vitro Generation
• Intracellular Generation

Segment by Circularization Method

• Ribozyme-Mediated Circularization
• Enzymatic Ligation
• Other

Segment by Ribozyme Route

• Group I Intron-Based
• Group II Intron-Based
• Other

Segment by Application

• Pharmaceutical and Biotechnology Companies
• CRO and CDMO Companies
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Circular RNA Generation Technology market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceutical and Biotechnology Companies, CRO and CDMO Companies, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact